Investigational drug · Phase 3
IMNN-001
Also called: IL-12 Plasmid with PEG-PEI-Cholesterol Lipopolymer, GEN-1
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "IMNN-001"
First trial start
2018
Sep 5, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMNN-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fallopian Tube Cancer
- Epithelial Ovarian Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer
- Primary Peritoneal Carcinoma
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IMNN-001" as an intervention, largest first.
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerPivotal-lookingRecruiting
ImunonIndustry
NCT06915025 · 500 participants (planned) · Start Jul 9, 2025 · Primary completion Oct 31, 2032
Drug: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer); Paclitaxel and 3 more · For: Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer and 1 more
Sites: Orlando, Florida; New Orleans, Louisiana; Detroit, Michigan · 11 sites in all
- Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)Pivotal-lookingActive, not recruiting
ImunonIndustry
NCT03393884 · 130 participants (planned) · Start Sep 5, 2018 · Primary completion Jul 25, 2024
Drug: IMNN-001; Carboplatin and 1 more · For: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Newport Beach, California · 21 sites in all
ImunonIndustry
NCT05739981 · 30 participants (planned) · Start Feb 10, 2023 · Primary completion Jun 30, 2027
Drug: Paclitaxel; Carboplatin and 2 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Baltimore, Maryland; New York, New York; Oklahoma City, Oklahoma · 4 sites in all
ImunonIndustry
NCT02480374 · 18 participants · Start Sep 2015 · Primary completion May 2017
Drug: IMNN-001 · For: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; St Louis, Missouri; Oklahoma City, Oklahoma · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer.
Anwer K, Sood S, Sparks J, et al. · Pharmaceutics 2026
- A severity-aware multi-task CNN-transformer framework for explainable diabetic foot ulcer triage and mobile deployment.
Abdullah, Ather MA, Fatima Z, et al. · Front Artif Intell 2026
- Rectal Bacteria and Antibiotic Resistance in Zoo Animals in Algeria.
Choual K, Tamendjari S, Peruzy MF, et al. · Antibiotics (Basel) 2026
- Studies on electrospun PVDF/Silanized hyperbranched polyester of Gen-1 nanofibers as Piezo and Triboelectric nanogenerators.
Balaraman I, Arun AP · Sci Rep 2026
- Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.
Thaker PH, Lindborg SR, Limon A, et al. · Expert Opin Investig Drugs 2026
- Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].
Thaker PH, Richardson DL, Hagemann AR, et al. · Gynecol Oncol 2025
Also in development for Fallopian Tube Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
- ZN-c3azenosertibPhase 34 trials
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma
- H1 receptor antagonistPhase 33 trials
Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer
- HS-20089Phase 33 trials
Hansoh BioMedical R&D Company · Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.